Incretin-based therapies in type 2 diabetes: a review of clinical results.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Diabetes Research and Clinical Practice

• Publication date

  2008-12-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.diabres.2008.10.003PMID 19022515
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.

  2008cited by this paper
• Efficacy and tolerability of vildagliptin in drug‐naïve patients with type 2 diabetes and mild hyperglycaemia *

  2008cited by this paper
• The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose.

  2008cited by this paper
• Cytokines and beta-cell biology: from concept to clinical translation.

  2008cited by this paper
• Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes *

  2008cited by this paper
• Cytokines and β-Cell Biology: from Concept to Clinical Translation

  2008cited by this paper
• Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 Diabetes

  2008cited by this paper
• Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 Diabetes

  2008cited by this paper
• Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea *

  2008cited by this paper
• Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 Diabetes

  2008cited by this paper
• Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes

  2008cited by this paper
• Glucolipotoxicity: fuel excess and beta-cell dysfunction.

  2008cited by this paper
• Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24‐week, double‐blind, randomized trial

  2008cited by this paper
• Evidence that vildagliptin attenuates deterioration of glycaemic control during 2‐year treatment of patients with type 2 diabetes and mild hyperglycaemia *

  2008cited by this paper
• Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis.

  2008cited by this paper
• Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin

  2007cited by this paper
• Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes

  2007influential reference
• Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24‐week, randomized, double‐blind study *

  2007cited by this paper
• Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.

  2007cited by this paper
• Vildagliptin in Drug-naïve Patients with Type 2 Diabetes: A 24-Week, Double-blind, Randomized, Placebo-controlled, Multiple-dose Study

  2007cited by this paper
• A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study

  2007cited by this paper
• The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes

  2007cited by this paper
• Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial

  2007cited by this paper
• beta-cell failure in diabetes and preservation by clinical treatment.

  2007cited by this paper
• Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug‐naïve patients with Type 2 diabetes

  2007influential reference
• Comparison of Vildagliptin and Rosiglitazone Monotherapy in Patients With Type 2 Diabetes

  2007influential reference
• Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes*

  2007cited by this paper
• Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo‐controlled study *

  2007cited by this paper
• The physiology of glucagon-like peptide 1.

  2007influential reference
• Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

  2007cited by this paper
• Fasting hyperglycemia impairs glucose- but not insulin-mediated suppression of glucagon secretion.

  2007cited by this paper
• Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.

  2007cited by this paper
• Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes.

  2007cited by this paper
• Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

  2006cited by this paper
• Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes.

  2006cited by this paper
• Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

  2006cited by this paper
• Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes

  2006cited by this paper
• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

  2006cited by this paper
• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus

  2006cited by this paper
• Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey.

  2006cited by this paper
• Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy

  2006cited by this paper
• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

  2006cited by this paper
• Efficacy and tolerability of the dipeptidyl peptidase‐4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes

  2006cited by this paper
• Exenatide Versus Insulin Glargine in Patients With Suboptimally Controlled Type 2 Diabetes: A Randomized TrialHeine RJ, for the GWAA Study Group (VU Univ, Amsterdam; et al) Ann Intern Med 143:559–569, 2005§

  2006cited by this paper
• Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes

  2005cited by this paper
• (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

  2005cited by this paper
• Improved glycaemic control with dipeptidyl peptidase‐4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response

  2005cited by this paper
• Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

  2005cited by this paper
• Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

  2005cited by this paper
• Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.

  2005cited by this paper
• Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans.

  2004cited by this paper
• Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes.

  2004cited by this paper
• Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.

  2004cited by this paper
• 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties.

  2003cited by this paper
• Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets.

  2003cited by this paper
• Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes.

  2003influential reference
• Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study.

  2002cited by this paper
• Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats.

  2002cited by this paper
• Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients.

  2001cited by this paper
• The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus.

  1999cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM

  1997cited by this paper
• Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

  1995cited by this paper
• The incretin concept today

  1979cited by this paper

• Adipose Tissue Secretion Pattern Influences β-Cell Wellness in the Transition from Obesity to Type 2 Diabetes

  2022cites this paper
• A REVIEW ON RECENT ADVANCES IN THE TREATMENT OF DIABETES MELLITUS.

  2022cites this paper
• Evaluation of the relationship between weight change and glycemic control after initiation of antidiabetic therapy in patients with type 2 diabetes using electronic medical record data.

  2014cites this paper
• Impact of Adherence and Weight Loss on Glycemic Control in Patients with Type 2 Diabetes: Cohort Analyses of Integrated Medical Record, Pharmacy Claims, and Patient-Reported Data

  2014cites this paper
• The effect of Cyclopia maculata extract on β-cell function, protection against oxidative stress and cell survival

  2014cites this paper
• Oral delivery of therapeutic protein/peptide for diabetes--future perspectives.

  2013cites this paper
• The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.

  2013cites this paper
• Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats.

  2012cites this paper
• Investigations of Altered Proteome Dynamics in Calorie Restriction, Insulin Resistance and Type 2 Diabetes

  2012cites this paper
• Self-assembling glucagon-like peptide 1-mimetic peptide amphiphiles for enhanced activity and proliferation of insulin-secreting cells.

  2012cites this paper
• Efficacy of saxagliptin as an add-on to oral monotherapy in the phase 3 clinical development program: predictive factors of the treatment response in type 2 diabetes.

  2011cites this paper
• Genetic disparities in the development of type 2 diabetes among African Americans

  2011influential citation
• Advances in the treatment of type 2 diabetes mellitus.

  2011influential citation
• Once-weekly exenatide in type 2 diabetes

  2011cites this paper
• Interpretation of PET scan results at varying degrees of blood glucose in diabetic patients with lymphoma: an experience of 25 cases of Non Hodgkin Lymphomas from southern India

  2011cites this paper
• A thesis submitted for the degree of Doctor of Philosophy

  2011cites this paper
• GLP‐1 Biology, Signaling Mechanisms, Physiology, and Clinical Studies

  2011cites this paper
• Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review

  2010cites this paper
• Incretin-based therapy and type 2 diabetes.

  2010cites this paper
• Current developments in the treatment of diabetes: the incretin therapies

  2010cites this paper
• Preventing type 2 diabetes mellitus: room for residual risk reduction after lifestyle changes?

  2010cites this paper
• Future perspectives for insulinotropic agents in the treatment of type 2 diabetes–DPP‐4 inhibitors and sulphonylureas

  2010cites this paper
• Once-Weekly GLP-1 Agonists: How Do They Differ from Exenatide and Liraglutide?

  2010cites this paper
• Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review

  2010cites this paper
• Evaluation of a pharmacist-led medication management program in high-risk diabetic patients: impact on clinical outcomes, medication adherence, and pharmacy costs

  2009cites this paper
• Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy

  2009cites this paper
• mellitus by drugs modulating the incretin system

  2009cites this paper
• Treatment of type 2 diabetes with glucagon‐like peptide‐1 receptor agonists

  2009cites this paper